Home Cart Sign in  
Chemical Structure| 790702-57-7 Chemical Structure| 790702-57-7

Structure of NGI-1
CAS No.: 790702-57-7

Chemical Structure| 790702-57-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML414 (NGI-1) is an inhibitor of oligosaccharyltransferase (OST) with IC50 of 1.1 µM by targeting catalytic subunits STT3A and STT3B.

Synonyms: ML414; N-linked Glycosylation Inhibitor 1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NGI-1

CAS No. :790702-57-7
Formula : C17H22N4O3S2
M.W : 394.51
SMILES Code : O=C(NC1=NC=C(C)S1)C2=CC(S(=O)(N(C)C)=O)=CC=C2N3CCCC3
Synonyms :
ML414; N-linked Glycosylation Inhibitor 1
MDL No. :MFCD06358908
InChI Key :QPKGRLIYJGBKJL-UHFFFAOYSA-N
Pubchem ID :2519269

Safety of NGI-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
H1975-OR 10μM 5 days NGI-1 reduced proliferation of H1975-OR cells by ~70% and caused G1 cell cycle arrest. Cancer Res. 2018 Sep 1;78(17):5094-5106.
HCC827-GR 10μM 5 days NGI-1 reduced proliferation of HCC827-GR cells by ~80% and caused G1 cell cycle arrest. Cancer Res. 2018 Sep 1;78(17):5094-5106.
PC9-GR2 10μM 5 days NGI-1 reduced proliferation of PC9-GR2 cells by ~90% and caused G1 cell cycle arrest. Cancer Res. 2018 Sep 1;78(17):5094-5106.
Huh7 cells 8 μM 48 hours NGI-1 significantly reduced DENV and ZIKV infectivity Cell Rep. 2017 Dec 12;21(11):3032-3039.
PC9-GR1 10μM 5 days NGI-1 reduced proliferation of PC9-GR1 cells by ~90% and caused G1 cell cycle arrest. Cancer Res. 2018 Sep 1;78(17):5094-5106.
T98G 10 μM 48 hours NGI-1 reduced phosphorylation of PDGFR but had no significant effect on radiosensitivity in T98G cells. Clin Cancer Res. 2019 Jan 15;25(2):784-795.
U251 10 μM 48 hours NGI-1 reduced phosphorylation of MET but had no significant effect on radiosensitivity in U251 cells. Clin Cancer Res. 2019 Jan 15;25(2):784-795.
SKMG3 10 μM 48 hours NGI-1 reduced protein levels of ErbB2 and ErbB3, and enhanced radiosensitivity in SKMG3 cells. Clin Cancer Res. 2019 Jan 15;25(2):784-795.
D54 10 μM 48 hours NGI-1 reduced glycosylation and phosphorylation of EGFR, ErbB2, and ErbB3, and enhanced radiosensitivity in D54 cells. Clin Cancer Res. 2019 Jan 15;25(2):784-795.
HN4 cells 0-20 μmol/L 24 hours Inhibited STT3B-mediated glycosylation of EREG, leading to its degradation and suppression of PDL1 Int J Oral Sci. 2024 Jul 1;16(1):47.
HEK293T-ACE2 cells 1 μM 48 hours To evaluate the effect of NGI-1 on SARS-CoV-2 and its variant pseudovirus infectivity, results showed that NGI-1 significantly reduced pseudovirus infectivity. EBioMedicine. 2021 Dec;74:103712.
Vero E6 cells 1.863 μM 1 hour pretreatment To evaluate the effect of NGI-1 on SARS-CoV-2 infectivity, results showed that NGI-1 significantly reduced viral protein expression and infectivity. EBioMedicine. 2021 Dec;74:103712.
HEK293T cells 10 μM 24 hours To evaluate the effect of NGI-1 on SARS-CoV-2 spike protein glycosylation, results showed that NGI-1 treatment reduced the molecular weight of spike protein, indicating glycosylation inhibition. EBioMedicine. 2021 Dec;74:103712.
HEK293 cells 1 μM and higher 48 hours NGI-1 significantly inhibited DENV and ZIKV replication with EC50 values of 0.85 μM and 2.2 μM, respectively Cell Rep. 2017 Dec 12;21(11):3032-3039.
Madin-Darby canine kidney (MDCK) epithelial cells 10.0 μM 1 hour to 24 hours To evaluate the effect of NGI-1 on influenza virus growth, results showed that NGI-1 treatment significantly reduced the infectious titers of influenza viruses mBio. 2022 Apr 26;13(2):e0298321.
Normal human bronchial epithelial (NHBE) cells 10.0 μM 1 hour to 24 hours To evaluate the effect of NGI-1 on influenza virus growth, results showed that NGI-1 treatment significantly reduced the infectious titers of all tested influenza viruses mBio. 2022 Apr 26;13(2):e0298321.
MCF7 breast carcinoma cells 10 µM 48 hours To evaluate the inhibitory effect of NGI-1 on protein glycosylation and its impact on entosis. Results showed that NGI-1 significantly increased the number of entotic structures and increased the proportion of apoptotic+necrotic cells after ROCKi treatment. Cell Death Dis. 2022 Aug 24;13(8):730.
293T cells 10 μM 24 hours Inhibited glycosylation of LAMP1 and LAMP2A, similar to the effects observed with ALKBH1 overexpression Cell Mol Life Sci. 2024 Mar 12;81(1):130.
HeLa cells 10 μM 24 hours Inhibited glycosylation of LAMP1 and LAMP2A, similar to the effects observed with ALKBH1 overexpression Cell Mol Life Sci. 2024 Mar 12;81(1):130.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female athymic Swiss nu/nu mice HCC827-GR and H1975-OR xenografts Intravenous injection 20 mg/kg Three times per week for a total of 8 doses NGI-1 nanoparticles significantly delayed the growth of HCC827-GR and H1975-OR xenografts, with enhanced effects when combined with EGFR TKIs. Cancer Res. 2018 Sep 1;78(17):5094-5106.
Nude mice D54 and SKMG3 xenograft models Intravenous injection 20 mg/kg Every other day for a total of 3 doses NGI-1 NPs significantly inhibited the growth of D54 and SKMG3 xenografts and showed better efficacy when combined with radiotherapy. Clin Cancer Res. 2019 Jan 15;25(2):784-795.
C57BL/6 mice MTCQ1 syngeneic model Intraperitoneal injection 10 mg/kg 4 times per week, during treatment Combination of NGI-1 with anti-PDL1 therapy significantly enhanced immunotherapy efficacy Int J Oral Sci. 2024 Jul 1;16(1):47.
BALB/c nude mice Xenograft tumor model Intraperitoneal injection 20 mg/kg 3 times per week for a total of 8 doses NGI-1 significantly inhibited the growth of PC-9 xenograft tumors, reducing tumor volume and wet weight Transl Lung Cancer Res. 2022 Jun;11(6):1089-1107

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.67mL

2.53mL

1.27mL

25.35mL

5.07mL

2.53mL

References

 

Historical Records

Categories